Pharsight

Drugs that contain Bosutinib Monohydrate

1. Bosulif patents expiration

BOSULIF's oppositions filed in EPO
BOSULIF IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6002008 PF PRISM CV Substituted 3-cyano quinolines
Mar, 2018

(6 years ago)

USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(a month ago)

US7767678 PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6002008 PF PRISM CV Substituted 3-cyano quinolines
Mar, 2018

(6 years ago)

USRE42376

(Pediatric)

PF PRISM CV Substituted 3-cyanoquinolines
Oct, 2024

(4 months from now)

US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(1 year, 6 months from now)

US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(1 year, 6 months from now)

US7919625

(Pediatric)

PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Jun, 2026

(2 years from now)

US7417148

(Pediatric)

PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Jun, 2026

(2 years from now)

US7767678

(Pediatric)

PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
May, 2027

(2 years from now)

US11103497 PF PRISM CV Treatment of imatinib resistant leukemia
Feb, 2034

(9 years from now)

US11103497

(Pediatric)

PF PRISM CV Treatment of imatinib resistant leukemia
Aug, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-163) Dec 19, 2024
Orphan Drug Exclusivity(ODE-444) Sep 26, 2030
New Indication(I-923) Sep 26, 2026
Pediatric Exclusivity(PED) Mar 26, 2027
New Indication(I-759) Dec 19, 2020
Orphan Drug Exclusivity(ODE) Sep 04, 2019
Orphan Drug Exclusivity(ODE-30) Sep 04, 2019
New Chemical Entity Exclusivity(NCE) Sep 04, 2017

NCE-1 date: 26 March, 2026

Market Authorisation Date: 04 September, 2012

Treatment: A method of treating a neoplasm; A method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy; A method for treating a bcrabl positive leukemi...

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents